Eur J Immunol 2002 Sep;32(9):2687-97
Jabs C, Greve B, Chang TT, Sobel RA, Sharpe AH, Kuchroo VK.
Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
B7 costimulatory molecules play an important role in inducing autoimmunity, tumor immunity, and transplant rejection, and therapeutic manipulation of B7 is being investigated in human diseases.
To determine whether B7 costimulation is essential for inducing autoimmunity on different genetic backgrounds, we backcrossed B7.1/B7.2 deficient ((-/-)) mice on to the C57BL/6 (B6) and SJLbackgrounds and induced experimental autoimmune encephalomyelitis (EAE) in these mice.
B7.1/B7.2(-/-) mice on the B6 background were resistant to EAE induced with MOG 35-55, whereas the SJL B7.1/B7.2(-/-) mice were susceptible to PLP 139-151 or PLP 178-191-induced EAE.
The SJL B7.1/B7.2(-/-) mice had a qualitatively different lesion pattern in that they showed increased white matter vacuolation compared to wild-type SJL mice when immunized with either PLP 139-151 or PLP 178-191.
(B6xSJL)F1 B7.1/B7.2(+/+) mice were susceptible to EAE whereas (B6xSJL)F1 B7.1/B7.2(-/-) mice were resistant to EAE induced with either encephalitogenic peptide.
Thus, genetic background determines the B7 requirement for inducing autoimmunity.
These data have important implications for developing B7-based immunotherapies for human diseases.